[ad_1]
Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen brokerages that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $198.2667.
A number of analysts have commented on DGX shares. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a research note on Monday, December 29th. Evercore ISI lifted their target price on shares of Quest Diagnostics from $185.00 to $190.00 and gave the stock an “in-line” rating in a research report on Wednesday, October 8th. UBS Group lifted their target price on Quest Diagnostics from $180.00 to $190.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Finally, Barclays upgraded Quest Diagnostics from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday.
View Our Latest Stock Report on DGX
Insider Activity
In other news, SVP Mark E. Delaney sold 7,946 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total value of $1,488,683.10. Following the sale, the senior vice president directly owned 7,530 shares of the company’s stock, valued at approximately $1,410,745.50. This represents a 51.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total transaction of $239,700.00. Following the completion of the transaction, the director directly owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. The trade was a 6.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,289 shares of company stock worth $12,318,360 over the last ninety days. Company insiders own 8.16% of the company’s stock.
Institutional Trading of Quest Diagnostics
A number of hedge funds have recently made changes to their positions in DGX. Brighton Jones LLC bought a new stake in Quest Diagnostics during the fourth quarter worth about $323,000. Janney Montgomery Scott LLC lifted its position in shares of Quest Diagnostics by 11.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 20,142 shares of the medical research company’s stock worth $3,618,000 after purchasing an additional 2,132 shares during the period. PFG Investments LLC lifted its holdings in Quest Diagnostics by 4.9% in the second quarter. PFG Investments LLC now owns 1,952 shares of the medical research company’s stock worth $351,000 after buying an additional 92 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Quest Diagnostics by 5.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,407 shares of the medical research company’s stock valued at $2,768,000 after purchasing an additional 830 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new position in Quest Diagnostics during the second quarter valued at $35,000. 88.06% of the stock is owned by institutional investors.
Quest Diagnostics Stock Performance
Shares of Quest Diagnostics stock opened at $186.90 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.13 and a quick ratio of 1.04. Quest Diagnostics has a one year low of $157.20 and a one year high of $197.55. The business has a 50-day simple moving average of $181.36 and a 200 day simple moving average of $180.73. The firm has a market capitalization of $20.79 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 2.37 and a beta of 0.66.
Quest Diagnostics Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 28th. Investors of record on Tuesday, January 13th were paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Tuesday, January 13th. Quest Diagnostics’s payout ratio is presently 37.56%.
Quest Diagnostics Company Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Featured Stories
Receive News & Ratings for Quest Diagnostics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quest Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link











